Most importantly, we saw significantly higher numbers of tumor-infiltrating, OVA-specific cytotoxic CD8+ T cells in PeptiCRAd VALO-mD901-OVA-treated tumors compared to other treatment groups. This evidence concerns the gene CD8A and neoplasm.